Pathogenesis of giant cell arteritis: More than just an inflammatory condition?

Autoimmunity Reviews

Volumn 9, Issue 10, 2010, Pages 635-645

  Ly, Kim Heang ^a,b   Régent, Alexis ^a   Tamby, Mathieu C ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Giant cell arteritis; Inflammation; Pathogenesis; Remodeling; T lymphocytes

Indexed keywords

BACTERIAL DNA; BACTERIAL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; AORTA OCCLUSION; ARTERY INTIMA PROLIFERATION; ARTERY MUSCLE; BACTERIAL INFECTION; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ETHNICITY; GENETIC PREDISPOSITION; GIANT CELL; GIANT CELL ARTERITIS; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INDEL MUTATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; VIRUS INFECTION;

ANIMALS; ARTERIES; AUTOIMMUNITY; CELL COMMUNICATION; ENDOTHELIUM, VASCULAR; GIANT CELL ARTERITIS; HUMANS; HYPERPLASIA; INFLAMMATION; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; T-LYMPHOCYTES;

EID: 77955274178     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.05.002     Document Type: Review

References (170)

1. Hunder G.G. Epidemiology of giant-cell arteritis. Cleve Clin J Med 2002, 69(Suppl 2):SII79-SII82.
2. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Lopez-Diaz M.J., Miranda-Filloy J.A., Gonzalez-Juanatey C., Martin J., et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
3. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
4. Reinhold-Keller E., Zeidler A., Gutfleisch J., Peter H.H., Raspe H.H., Gross W.L. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000, 39:1396-1402.
5. Kobayashi S., Yano T., Matsumoto Y., Numano F., Nakajima N., Yasuda K., et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003, 49:594-598.
6. Liozon F. Horton's disease. Ann Med Interne (Paris). 1989, 140:122-141.
7. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005, 84:269-276.
8. Aiello P.D., Trautmann J.C., McPhee T.J., Kunselman A.R., Hunder G.G. Visual prognosis in giant cell arteritis. Ophthalmology 1993, 100:550-555.
9. Liozon E., Herrmann F., Ly K., Robert P.Y., Loustaud V., Soria P., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001, 111:211-217.
10. Salvarani C., Hunder G.G. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999, 42:1259-1266.
11. Gonzalez-Gay M.A., Lopez-Diaz M.J., Barros S., Garcia-Porrua C., Sanchez-Andrade A., Paz-Carreira J., et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). 2005, 84:277-290.
12. Myklebust G., Gran J.T. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996, 35:1161-1168.
13. Hunder G.G., Sheps S.G., Allen G.L., Joyce J.W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975, 82:613-618.
14. Andersson R., Malmvall B.E., Bengtsson B.A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986, 220:465-469.
15. Lie J.T. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990, 33:1074-1087.
16. Duhaut P., Bosshard S., Ducroix J.P. Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Méd 2004, 33:1403-1408.
17. Weyand C.M., Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 2003, 349:160-169.
18. Cid M.C., Hernandez-Rodriguez J., Esteban M.J., Cebrian M., Gho Y.S., Font C., et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002, 106:1664-1671.
19. Schmits R., Kubuschok B., Schuster S., Preuss K.D., Pfreundschuh M. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002, 127:379-385.
20. Baiu D.C., Barger B., Sandor M., Fabry Z., Hart M.N. Autoantibodies to vascular smooth muscle are pathogenic for vasculitis. Am J Pathol 2005, 166:1851-1860.
21. Liu N.H., LaBree L.D., Feldon S.E., Rao N.A. The epidemiology of giant cell arteritis: a 12-year retrospective study. Ophthalmology 2001, 108:1145-1149.
22. Bielory L., Ogunkoya A., Frohman L.P. Temporal arteritis in blacks. Am J Med 1989, 86:707-708.
23. Chaudhry I.A., Shamsi F.A., Elzaridi E., Arat Y.O., Bosley T.M., Riley F.C. Epidemiology of giant-cell arteritis in an Arab population: a 22-year study. Br J Ophthalmol 2007, 91:715-718.
24. Hu Z., Yang Q., Zeng S., Li J., Wu X., Cao L., et al. Giant cell arteritis in China: a prospective investigation. Angiology 2002, 53:457-463.
25. Nordborg E., Bengtsson B.A. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med 1990, 227:233-236.
26. Haugeberg G., Paulsen P.Q., Bie R.B. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000, 27:2624-2627.
27. Baldursson O., Steinsson K., Bjornsson J., Lie J.T. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 1994, 37:1007-1012.
28. Machado E.B., Michet C.J., Ballard D.J., Hunder G.G., Beard C.M., Chu C.P., et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 1988, 31:745-749.
29. Salvarani C., Crowson C.S., O'Fallon W.M., Hunder G.G., Gabriel S.E. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004, 51:264-268.
30. Salvarani C., Macchioni P., Zizzi F., Mantovani W., Rossi F., Castri C., et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991, 34:351-356.
31. Gonzalez-Gay M.A., Miranda-Filloy J.A., Lopez-Diaz M.J., Perez-Alvarez R., Gonzalez-Juanatey C., Sanchez-Andrade A., et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007, 86:61-68.
32. Smith C.A., Fidler W.J., Pinals R.S. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 1983, 26:1214-1219.
33. Ramstead C.L., Patel A.D. Giant cell arteritis in a neuro-ophthalmology clinic in Saskatoon, 1998-2003. Can J Ophthalmol 2007, 42:295-298.
34. Smeeth L., Cook C., Hall A.J. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006, 65:1093-1098.
35. Duhaut P., Pinede L., Demolombe-Rague S., Dumontet C., Ninet J., Seydoux D., et al. Giant cell arteritis and polymyalgia rheumatica: are pregnancies a protective factor? A prospective, multicentre case-control study. GRACG (Groupe de Recherche sur l'Arterite a Cellules Geantes). Rheumatology (Oxford). 1999, 38:118-123.
36. Larsson K., Mellstrom D., Nordborg E., Oden A. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis 2006, 65:529-532.
37. Duhaut P., Pinede L., Demolombe-Rague S., Loire R., Seydoux D., Ninet J., et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998, 41:1960-1965.
38. Banks P.M., Cohen M.D., Ginsburg W.W., Hunder G.G. Immunohistologic and cytochemical studies of temporal arteritis. Arthritis Rheum 1983, 26:1201-1207.
39. Wagner A.D., Gerard H.C., Fresemann T., Schmidt W.A., Gromnica-Ihle E., Hudson A.P., et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000, 43:1543-1551.
40. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004, 199:173-183.
41. Pryshchep O., Ma-Krupa W., Younge B.R., Goronzy J.J., Weyand C.M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008, 118:1276-1284.
42. Krupa W.M., Dewan M., Jeon M.S., Kurtin P.J., Younge B.R., Goronzy J.J., et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002, 161:1815-1823.
43. Grunewald J., Andersson R., Rydberg L., Gigliotti D., Schaufelberger C., Hansson G.K., et al. CD4+ and CD8+ T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis. Arthritis Rheum 1994, 37:1221-1227.
44. Martinez-Taboada V., Hunder N.N., Hunder G.G., Weyand C.M., Goronzy J.J. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med 1996, 74:695-703.
45. Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994, 121:484-491.
46. Brack A., Geisler A., Martinez-Taboada V.M., Younge B.R., Goronzy J.J., Weyand C.M. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997, 3:530-543.
47. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
48. Deng J., Younge B.R., Olshen R.A., Goronzy J.J., Weyand C.M. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010, 121:906-915.
49. Wagner A.D., Bjornsson J., Bartley G.B., Goronzy J.J., Weyand C.M. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996, 148:1925-1933.
50. McColl S.R. Chemokines and dendritic cells: a crucial alliance. Immunol Cell Biol 2002, 80:489-496.
51. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
52. Roche N.E., Fulbright J.W., Wagner A.D., Hunder G.G., Goronzy J.J., Weyand C.M. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993, 36:1286-1294.
53. Weyand C.M., Wagner A.D., Bjornsson J., Goronzy J.J. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest. 1996, 98:1642-1649.
54. Nikkari S.T., Hoyhtya M., Isola J., Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996, 149:1427-1433.
55. Segarra M., Garcia-Martinez A., Sanchez M., Hernandez-Rodriguez J., Lozano E., Grau J.M., et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007, 66:1429-1435.
56. Rodriguez-Pla A., Bosch-Gil J.A., Rossello-Urgell J., Huguet-Redecilla P., Stone J.H., Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005, 112:264-269.
57. Rittner H.L., Kaiser M., Brack A., Szweda L.I., Goronzy J.J., Weyand C.M. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999, 84:1050-1058.
58. Rittner H.L., Hafner V., Klimiuk P.A., Szweda L.I., Goronzy J.J., Weyand C.M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest. 1999, 103:1007-1013.
59. Fingerle J., Johnson R., Clowes A.W., Majesky M.W., Reidy M.A. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989, 86:8412-8416.
60. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991, 253:1129-1132.
61. Kaiser M., Weyand C.M., Bjornsson J., Goronzy J.J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998, 41:623-633.
62. Kaiser M., Younge B., Bjornsson J., Goronzy J.J., Weyand C.M. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999, 155:765-774.
63. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
64. Clowes A.W., Clowes M.M., Au Y.P., Reidy M.A., Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990, 67:61-67.
65. Xu F., Ji J., Li L., Chen R., Hu W.C. Adventitial fibroblasts are activated in the early stages of atherosclerosis in the apolipoprotein E knockout mouse. Biochem Biophys Res Commun 2007, 352:681-688.
66. Shi Y., O'Brien J.E., Fard A., Mannion J.D., Wang D., Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996, 94:1655-1664.
67. Li G., Chen S.J., Oparil S., Chen Y.F., Thompson J.A. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation 2000, 101:1362-1365.
68. Zalewski A., Shi Y. Vascular myofibroblasts. Lessons from coronary repair and remodeling. Arterioscler Thromb Vasc Biol 1997, 17:417-422.
69. Shi Y., O'Brien J.E., Mannion J.D., Morrison R.C., Chung W., Fard A., et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997, 95:2684-2693.
70. Siow R.C., Mallawaarachchi C.M., Weissberg P.L. Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc Res 2003, 59:212-221.
71. Wilcox J.N., Waksman R., King S.B., Scott N.A. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys 1996, 36:789-796.
72. Shi Y., O'Brien J.E., Fard A., Zalewski A. Transforming growth factor-beta 1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol 1996, 16:1298-1305.
73. Smith J.D., Bryant S.R., Couper L.L., Vary C.P., Gotwals P.J., Koteliansky V.E., et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999, 84:1212-1222.
74. Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2006, 3:94-101.
75. Hu Y., Zhang Z., Torsney E., Afzal A.R., Davison F., Metzler B., et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004, 113:1258-1265.
76. Rotmans J.I., Heyligers J.M., Verhagen H.J., Velema E., Nagtegaal M.M., de Kleijn D.P., et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 2005, 112:12-18.
77. Folkow B., Svanborg A. Physiology of cardiovascular aging. Physiol Rev 1993, 73:725-764.
78. Han J.W., Shimada K., Ma-Krupa W., Johnson T.L., Nerem R.M., Goronzy J.J., et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ Res 2008, 102:546-553.
79. Tobon G.J., Alard J.E., Youinou P., Jamin C. Are autoantibodies triggering endothelial cell apoptosis really pathogenic?. Autoimmun Rev 2009, 8:605-610.
80. Kemp A. Monozygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmol (Copenh). 1977, 55:183-190.
81. Wernick R., Davey M., Bonafede P. Familial giant cell arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 1994, 12:63-66.
82. Fietta P., Manganelli P., Zanetti A., Neri T.M. Familial giant cell arteritis and polymyalgia rheumatica: aggregation in 2 families. J Rheumatol 2002, 29:1551-1555.
83. Raptis L., Pappas G., Akritidis N. Horton's three sisters: familial clustering of temporal arteritis. Clin Rheumatol 2007, 26:1997-1998.
84. Liozon E., Ouattara B., Rhaiem K., Ly K., Bezanahary H., Loustaud V., et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol 2009, 27:S89-S94.
85. Gonzalez-Gay M.A., Garcia-Porrua C., Hajeer A.H., Dababneh A., Ollier W.E. HLA-DRB1*04 may be a marker of severity in giant cell arteritis. Ann Rheum Dis 2000, 59:574-575.
86. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Hajeer A.H., Branas F., Dababneh A., et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000, 79:283-292.
87. Rauzy O., Fort M., Nourhashemi F., Alric L., Juchet H., Ecoiffier M., et al. Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998, 57:380-382.
88. Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992, 90:2355-2361.
89. Salvarani C., Casali B., Boiardi L., Ranzi A., Macchioni P., Nicoli D., et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000, 27:1215-1221.
90. Amoli M.M., Shelley E., Mattey D.L., Garcia-Porrua C., Thomson W., Hajeer A.H., et al. Lack of association between intercellular adhesion molecule-1 gene polymorphisms and giant cell arteritis. J Rheumatol 2001, 28:1600-1604.
91. Mattey D.L., Hajeer A.H., Dababneh A., Thomson W., Gonzalez-Gay M.A., Garcia-Porrua C., et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000, 43:1749-1755.
92. Boiardi L., Casali B., Nicoli D., Farnetti E., Chen Q., Macchioni P., et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003, 30:2160-2164.
93. Rueda B., Lopez-Nevot M.A., Lopez-Diaz M.J., Garcia-Porrua C., Martin J., Gonzalez-Gay M.A. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005, 32:1737-1741.
94. Amoli M.M., Garcia-Porrua C., Llorca J., Ollier W.E., Gonzalez-Gay M.A. Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003, 30:2019-2022.
95. Gonzalez-Gay M.A., Oliver J., Sanchez E., Garcia-Porrua C., Paco L., Lopez-Nevot M.A., et al. Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2005, 32:2178-2182.
96. Nordborg C., Nordborg E., Petursdottir V., LaGuardia J., Mahalingam R., Wellish M., et al. Search for varicella zoster virus in giant cell arteritis. Ann Neurol 1998, 44:413-414.
97. Helweg-Larsen J., Tarp B., Obel N., Baslund B. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford). 2002, 41:445-449.
98. Rodriguez-Pla A., Bosch-Gil J.A., Echevarria-Mayo J.E., Rossello-Urgell J., Solans-Laque R., Huguet-Redecilla P., et al. No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis. J Clin Virol 2004, 31:11-15.
99. Alvarez-Lafuente R., Fernandez-Gutierrez B., Jover J.A., Judez E., Loza E., Clemente D., et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 2005, 64:780-782.
100. Cooper R.J., D'Arcy S., Kirby M., Al-Buhtori M., Rahman M.J., Proctor L., et al. Infection and temporal arteritis: a PCR-based study to detect pathogens in temporal artery biopsy specimens. J Med Virol 2008, 80:501-505.
101. Fest T., Mougin C., Dupond J.L. Giant cell arteritis. Ann Intern Med 1996, 124:927-928.
102. Gabriel S.E., Espy M., Erdman D.D., Bjornsson J., Smith T.F., Hunder G.G. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999, 42:1255-1258.
103. Cankovic M., Zarbo R.J. Failure to detect human herpes simplex virus, cytomegalovirus, and Epstein-Barr virus viral genomes in giant cell arteritis biopsy specimens by real-time quantitative polymerase chain reaction. Cardiovasc Pathol 2006, 15:280-286.
104. Powers J.F., Bedri S., Hussein S., Salomon R.N., Tischler A.S. High prevalence of herpes simplex virus DNA in temporal arteritis biopsy specimens. Am J Clin Pathol 2005, 123:261-264.
105. Duhaut P., Bosshard S., Calvet A., Pinede L., Demolombe-Rague S., Dumontet C., et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. J Rheumatol 1999, 26:361-369.
106. Njau F., Ness T., Wittkop U., Pancratz T., Eickhoff M., Hudson A.P., et al. No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods. J Clin Microbiol 2009, 47:1899-1901.
107. Haugeberg G., Bie R., Nordbo S.A. Chlamydia pneumoniae not detected in temporal artery biopsies from patients with temporal arteritis. Scand J Rheumatol 2000, 29:127-128.
108. Regan M.J., Wood B.J., Hsieh Y.H., Theodore M.L., Quinn T.C., Hellmann D.B., et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002, 46:1056-1060.
109. Lavignac C., Jauberteau-Marchan M.O., Liozon E., Vidal E., Catanzano G., Liozon F. Immunohistochemical study of lesions in Horton's temporal arteritis before and during corticotherapy. Rev Méd Interne 1996, 17:814-820.
110. Chatelain D., Duhaut P., Schmidt J., Loire R., Bosshard S., Guernou M., et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 2009, 68:84-88.
111. Liozon E., Roblot P., Paire D., Loustaud V., Liozon F., Vidal E., et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford). 2000, 39:1089-1094.
112. Duhaut P., Berruyer M., Pinede L., Demolombe-Rague S., Loire R., Seydoux D., et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998, 41:701-709.
113. Manna R., Latteri M., Cristiano G., Todaro L., Scuderi F., Gasbarrini G. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol 1998, 37:208-210.
114. Liozon E., Roussel V., Roblot P., Liozon F., Preud'Homme J.L., Loustaud V., et al. Absence of anti-beta2 glycoprotein I antibodies in giant cell arteritis: a study of 45 biopsy-proven cases. Br J Rheumatol 1998, 37:1129-1131.
115. Cid M.C., Cervera R., Font J., Lopez-Soto A., Pallares L., Navarro M., et al. Late thrombotic events in patients with temporal arteritis and anticardiolipin antibodies. Clin Exp Rheumatol 1990, 8:359-363.
116. Liozon F., Jauberteau-Marchan M.O., Boutros-Toni F., Barrier J.H., Dupond J.L., Roblot P., et al. Anticardiolipin antibodies and Horton disease. Ann Med Interne (Paris). 1995, 146:541-547.
117. Navarro M., Cervera R., Font J., Reverter J.C., Monteagudo J., Escolar G., et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 1997, 6:521-526.
118. Servettaz A., Guilpain P., Tamas N., Kaveri S.V., Camoin L., Mouthon L. Natural anti-endothelial cell antibodies. Autoimmun Rev 2008, 7:426-430.
119. Domiciano D.S., Carvalho J.F., Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus 2009, 18:1233-1238.
120. Guilpain P., Mouthon L. Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases. Clin Rev Allergy Immunol 2008, 35:59-65.
121. Regent A., Dib H., Agard C., Camoin L., Weksler B., Broussard C., et al. Identification of target antigens of anti-endothelial-cell and anti-vascular-smooth-muscle-cell antibodies in patients with giant cell arteritis: a proteomic approach [abstract]. Arthritis Rheum 2009, 60:186.
122. Wick G., Knoflach M., Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004, 22:361-403.
123. Rajaiah R., Moudgil K.D. Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev 2009, 8:388-393.
124. Ohashi K., Burkart V., Flohe S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
125. Asea A., Rehli M., Kabingu E., Boch J.A., Bare O., Auron P.E., et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002, 277:15028-15034.
126. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009, 27:621-668.
127. Hernandez-Rodriguez J., Segarra M., Vilardell C., Sanchez M., Garcia-Martinez A., Esteban M.J., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107:2428-2434.
128. Pountain G., Hazleman B., Cawston T.E. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol 1998, 37:797-798.
129. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
130. Beasley D., McGuiggin M.E., Dinarello C.A. Human vascular smooth muscle cells produce an intracellular form of interleukin-1 receptor antagonist. Am J Physiol 1995, 269:C961-C968.
131. Dewberry R., Holden H., Crossman D., Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2394-2400.
132. Shepherd J., Little M.C., Nicklin M.J. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol. 2004, 122:665-669.
133. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320.
134. Nicklin M.J., Hughes D.E., Barton J.L., Ure J.M., Duff G.W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000, 191:303-312.
135. Shepherd J., Nicklin M.J. Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation 2005, 111:3135-3140.
136. Kemp A., Marner K., Nissen S.H., Heyn J., Kissmeyer-Nielsen F. HLA antigens in cases of giant cell arteritis. Acta Ophthalmol (Copenh). 1980, 58:1000-1004.
137. Hansen J.A., Healey L.A., Wilske K.R. Association between giant cell (temporal) arteritis and HLA-Cw3. Hum Immunol 1985, 13:193-198.
138. Cid M.C., Ercilla G., Vilaseca J., Sanmarti R., Villalta J., Ingelmo M., et al. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum 1988, 31:678-682.
139. Bignon J.D., Barrier J., Soulillou J.P., Martin P., Grolleau J.Y. HLA DR4 and giant cell arteritis. Tissue Antigens 1984, 24:60-62.
140. Richardson J.E., Gladman D.D., Fam A., Keystone E.C. HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum 1987, 30:1293-1297.
141. Weyand C.M., Hunder N.N., Hicok K.C., Hunder G.G., Goronzy J.J. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994, 37:514-520.
142. Combe B., Sany J., Le Quellec A., Clot J., Eliaou J.F. Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol 1998, 25:94-98.
143. Jacobsen S., Baslund B., Madsen H.O., Tvede N., Svejgaard A., Garred P. Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol 2002, 29:2148-2153.
144. Dababneh A., Gonzalez-Gay M.A., Garcia-Porrua C., Hajeer A., Thomson W., Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998, 25:2140-2145.
145. Martinez-Taboda V.M., Bartolome M.J., Lopez-Hoyos M., Blanco R., Mata C., Calvo J., et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum 2004, 34:454-464.
146. Gonzalez-Gay M.A., Di Giovine F.S., Silvestri T., Amoli M.M., Garcia-Porrua C., Thomson W., et al. Lack of association between IL-1 cluster and TNF-alpha gene polymorphisms and giant cell arteritis. Clin Exp Rheumatol 2002, 20:431.
147. Gonzalez-Gay M.A., Hajeer A.H., Dababneh A., Garcia-Porrua C., Mattey D.L., Amoli M.M., et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002, 20:179-184.
148. Salvarani C., Casali B., Farnetti E., Pipitone N., Nicoli D., Macchioni P., et al. Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. J Rheumatol 2005, 32:2173-2177.
149. Gonzalez-Gay M.A., Hajeer A.H., Dababneh A., Garcia-Porrua C., Amoli M.M., Llorca J., et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004, 22:S18-S20.
150. Amoli M.M., Gonzalez-Gay M.A., Zeggini E., Salway F., Garcia-Porrua C., Ollier W.E. Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis. J Rheumatol 2004, 31:2413-2417.
151. Boiardi L., Casali B., Farnetti E., Pipitone N., Nicoli D., Macchioni P., et al. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum 2006, 54:4011-4017.
152. Rueda B., Roibas B., Martin J., Gonzalez-Gay M.A. Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. J Rheumatol 2007, 34:1535-1539.
153. Amoli M.M., Garcia-Porrua C., Ollier W.E., Gonzalez-Gay M.A. Lack of association between macrophage migration inhibitory factor gene polymorphism and giant cell arteritis. J Rheumatol 2005, 32:74-76.
154. Amoli M.M., Salway F., Zeggini E., Ollier W.E., Gonzalez-Gay M.A. MCP-1 gene haplotype association in biopsy proven giant cell arteritis. J Rheumatol 2005, 32:507-510.
155. Salvarani C., Casali B., Nicoli D., Farnetti E., Macchioni P., Catanoso M.G., et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003, 48:3219-3223.
156. Rodriguez-Pla A., Beaty T.H., Savino P.J., Eagle R.C., Seo P., Soloski M.J. Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis. Arthritis Rheum 2008, 58:1849-1853.
157. Palomino-Morales R., Torres O., Vazquez-Rodriguez T.R., Morado I.C., Castaneda S., Callejas-Rubio J.L., et al. Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009, 36:1501-1506.
158. Rueda B., Miranda-Filloy J.A., Martin J., Gonzalez-Gay M.A. Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2008, 35:850-854.
159. Gonzalez-Gay M.A., Oliver J., Orozco G., Garcia-Porrua C., Lopez-Nevot M.A., Martin J. Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2005, 32:1510-1512.
160. Martin J., Perez-Armengol C., Miranda-Filloy J.A., Vilchez J.R., Lopez-Nevot M.A., Garcia-Porrua C., et al. Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain. J Rheumatol 2006, 33:285-288.
161. Palomino-Morales R., Vazquez-Rodriguez T.R., Morado I.C., Castaneda S., Ortego-Centeno N., Miranda-Filloy J.A., et al. Lack of association between STAT4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009, 36:1021-1025.
162. Torres O., Palomino-Morales R., Vazquez-Rodriguez T.R., Castaneda S., Morado I.C., Miranda-Filloy J.A., et al. Lack of association between TRAF1/C5 gene polymorphisms and biopsy-proven giant cell arteritis. J Rheumatol 2010, 37:131-135.
163. Torres O., Palomino-Morales R., Vazquez-Rodriguez T.R., Castaneda S., Morado I.C., Miranda-Filloy J.A., et al. Lack of association between IRF5 gene polymorphisms and biopsy-proven giant cell arteritis. J Rheumatol 2010, 37:136-140.
164. Morgan A.W., Robinson J.I., Barrett J.H., Martin J., Walker A., Babbage S.J., et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther 2006, 8:R109.
165. Gonzalez-Gay M.A., Rueda B., Vilchez J.R., Lopez-Nevot M.A., Robledo G., Ruiz M.P., et al. Contribution of MHC class I region to genetic susceptibility for giant cell arteritis. Rheumatology (Oxford). 2007, 46:431-434.
166. Salvarani C., Casali B., Farnetti E., Pipitone N., Nicoli D., Macchioni P.L., et al. 463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis. Ann Rheum Dis 2008, 67:485-488.
167. Palomino-Morales R., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., Martin J., Gonzalez-Gay M.A. C-reactive protein gene polymorphisms in biopsy-proven giant cell arteritis from Northwestern Spain. J Rheumatol 2009, 36:341-346.
168. Gonzalez-Gay M.A., Hajeer A.H., Dababneh A., Garcia-Porrua C., Amoli M.M., Thomson W., et al. Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2002, 20:133-138.
169. Salvarani C., Farnetti E., Casali B., Nicoli D., Wenlan L., Bajocchi G., et al. Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study. Arthritis Rheum 2002, 46:3099-3101.
170. Kennedy P.G., Grinfeld E., Esiri M.M. Absence of detection of varicella-zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritis. J Neurol Sci 2003, 215:27-29.